Related to ImmuPharma Regains Global Rights to Cephalon's Phase II Lupus Candidate

• Investigators Implicate Endolysosomal TLRs in Lupus Development
  
• Human Genome Sciences’ Value Skyrockets with Positive Late-Stage Data from Lupus Trial
  
• Pikamab Secures Patents that Will Enable Development of Theranostic for Lupus
  
• Cephalon Gains Option to Take Over BioAssets for $30M
  
• Teva Ponies Up €3.625B for Ratiopharm
  
• La Jolla Pharmaceutical Scores $6M Shot in Arm from Investors
  
• Noxxon Secures €33M to Push On with Clinical Development of Spiegelmers
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• Cephalon Gains FDA Nod on REMS for Antiepileptic Gabitril
  
• Human Genome Sciences and GSK’s Lupus Candidate Hits the Mark in Second Phase III Trial
  
• SuppreMol Wins $2.1M Funding for Clinical Development of Autoimmune Therapy
  
• Phase III Trial Demonstrates Benefits of Teva’s Laquinimod in MS Patients
  
• Merck BioManufacturing Network to Supply Anthera with Peptibody
  
• Biotech Acquisition Deals in 2010 that Topped $1B
  
• FDA Green-Lights HGS and GSK’s Systemic Lupus Erythematosus Drug Benlysta
  
• Cephalon to Spend $225M to Purchase Gemin X for Phase II SCLC Candidate
  
• Cephalon Makes $231M Overall Bid to Acquire ChemGenex for NDA-Ready CML Drug
  
• Valeant Takes Unsolicited $5.7B Cash Offer for Cephalon to Shareholders
  
• Cephalon Board Rejects Valeant’s $73 Per Share Unsolicited Takeover Bid
  
• Researchers Identify Serum Biomarkers to Diagnose SLE and Differentiate Disease Severity and Activity